Selective CDK9 Inhibitor Compounds for Lower-Toxicity Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CDK9 inhibitors exhibit a complex toxicity profile due to activity beyond CDK9, hindering their development for the treatment of cancer and other conditions.
Innovation Solution
Development of specific and selective CDK9 inhibitor compounds, including stereoisomers and pharmaceutically acceptable salts, for the treatment of cancers such as bladder cancer, prostate cancer, and leukemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK9 inhibitors are used to rapidly induce apoptosis in tumor cells, then cancer treatment efficacy is improved, but a complex toxicity profile develops due to activity beyond CDK9
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures (Structure I and II with defined R groups) that confer selectivity for CDK9 over other CDKs. The structural modifications at specific positions (R1-R6 substituents) create localized interactions that enhance binding specificity to CDK9's unique structural features, thereby improving therapeutic efficacy while reducing off-target toxicity.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations in Structures I and II) to optimize the inhibitor's selectivity profile. By adjusting molecular weight, hydrophobicity, and steric parameters through different R group combinations, the invention achieves enhanced CDK9 specificity while minimizing activity against other CDKs, thus reducing the complex toxicity profile.
2Adaptability or versatility
If non-selective CDK inhibitors are used to target multiple CDKs, then broad cancer coverage is achieved, but selective CDK9 inhibition cannot be realized
Solution Approach 1:
The patent applies segmentation by dividing the CDK inhibitor landscape into specific subclasses: CDK4/6 inhibitors, CDK9 inhibitors, and pan-CDK inhibitors. The invention focuses on developing highly selective CDK9 inhibitors (Structure I and II) that can be used alone or in combination with other targeted agents, allowing precise monotherapy or combination regimens tailored to specific cancer types without requiring broad non-specific CDK inhibition.
Data Source
AI summary
or a stereoisomer or salt (e.g., pharmaceutically acceptable salt) thereof, wherein R1, R2, R3, R4, R5, p, m, and n are as defined herein. Use of the compounds as a component of a pharmaceutical compositions and methods for their use are also provided.